Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C

Masayuki Hayashi; Yuko Kataoka; Kazushige Tachikawa; Hiroki Koguchi; Hiroshi Tanaka

doi:10.1016/j.diabres.2009.08.009

Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C

Diabetes Res Clin Pract. 2009 Nov;86(2):e19-21. doi: 10.1016/j.diabres.2009.08.009. Epub 2009 Sep 9.

Authors

Masayuki Hayashi¹, Yuko Kataoka, Kazushige Tachikawa, Hiroki Koguchi, Hiroshi Tanaka

Affiliation

¹ Department of Endocrinology and Metabolism, Chukyo Hospital, Nagoya 457-8510, Japan. masayuki_hayashi@chukyo-hosp.jp

PMID: 19744739
DOI: 10.1016/j.diabres.2009.08.009

Abstract

Currently, a combination therapy of pegylated (PEG) interferon (IFN) alpha-2b and ribavirin are being widely used for the treatment of chronic hepatitis C (CHC). We describe here a case of dual onset of type 1 DM accompanied by ketoacidosis, and Graves' disease during the combination therapy via the autoimmune process.

Publication types

Case Reports

MeSH terms

Antiviral Agents / adverse effects*
Antiviral Agents / therapeutic use
Autoimmune Diseases / chemically induced
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / complications
Female
Graves Disease / chemically induced*
Graves Disease / complications
Hepatitis C, Chronic / drug therapy*
Histocompatibility Antigens Class I / genetics
Humans
Interferon alpha-2
Interferon-alpha / adverse effects*
Interferon-alpha / therapeutic use
Middle Aged
Polyethylene Glycols / adverse effects*
Polyethylene Glycols / therapeutic use
Recombinant Proteins
Ribavirin / adverse effects*
Ribavirin / therapeutic use

Substances

Antiviral Agents
Histocompatibility Antigens Class I
Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
Ribavirin
peginterferon alfa-2b